Nuformix PLC Notice of Allowance of NXP002 Patent in Japan (8813Q)
October 23 2023 - 2:04AM
UK Regulatory
TIDMNFX
RNS Number : 8813Q
Nuformix PLC
23 October 2023
23 October 2023
Nuformix plc
("Nuformix" or the "Company")
Notice of Allowance of NXP002 Patent in Japan
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce that it has been issued with an
Official Decision to Grant Notice of Allowance for Japanese
National Phase Patent Application No. 2020-555115 entitled
"CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE".
NXP002 is the Company's lead asset and a potential novel inhaled
treatment for Idiopathic Pulmonary Fibrosis ("IPF"). The granted
patent describes a proprietary new form of the drug tranilast,
uniquely enabling delivery via an inhaled nebulised formulation.
Nuformix owns two patent applications relating to crystalline forms
of tranilast, one of which had already been granted globally. This
second patent application, which as has already been granted in the
US, specifically addresses the novel tranilast forms being
progressed by the Company as a potential novel IPF treatment.
Dr Dan Gooding, Executive Director of Nuformix, said: "I'm
delighted we have received this Official Decision to Grant from the
Japanese Patent Office. This provides confirmation that no prior
art exists in relation to NXP002, which is very important given
that this is the territory in which tranilast was first invented
and where the vast majority of considerable subsequent development
work has been conducted. The grant is therefore an important step
forward for our lead asset NXP002. We expect the European grant to
follow shortly, which will further support the Company's on-going
partnering activities."
Enquiries:
Nuformix plc
Dr Dan Gooding, Executive Director Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKZMZGMZMGFZM
(END) Dow Jones Newswires
October 23, 2023 02:04 ET (06:04 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Aug 2023 to Aug 2024